Surgeon General Jerome M. Adams, MD, MPH, made a surprise visit to AcademyHealth’s National Health Policy Conference Tuesday morning and took to the podium to declare that he wants to be the first surgeon general to issue a report showing the links between health and a healthy economy.
Surgeon General Jerome M. Adams, MD, MPH, made a surprise visit to AcademyHealth’s National Health Policy Conference Tuesday morning and took to the podium to declare that he wants to be the first surgeon general to issue a report showing the links between health and a healthy economy.
In his brief remarks, Adams discussed the need to address the opioid crisis with data and talked about using data to make issues more relevant to policy makers, especially for conversations around healthy economies and national security.
His unscheduled visit came on a day when Congress was slated to vote on a short-term continuing resolution (CR) to prevent a government shutdown. The CR includes funding for community health centers, but cuts almost $3 billion over 10 years from the Affordable Care Act’s Prevention and Public Health Fund. It also includes spending on defense programs.
Adams referenced the upcoming vote in Congress when he said he was also concerned about health and national security.
“Seven out of 10 of our youth are ineligible for military service,” he said. “Let me say that again. Seven out of 10 of our 18-to-24-year-olds are ineligible for military service.” Adams said it was either because they can’t pass a physical, have a criminal record, or don’t have the education requirements.
"We're a country that's less safe now because we're not as healthy as we could be," he said.
He told the audience that policy makers need to be told, “If you want a more prosperous community, look at the data that we have available.”
“As Surgeon General of the United States, my number 1 job is to communicate science and the priority of health to the American people,” Adams said.
Adams is an anesthesiologist and an expert in the field of substance abuse and joined the Trump administration last year.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More